Rational design of potent GSK3β inhibitors with selectivity for Cdk1 and Cdk2

被引：24
|
作者：
Lesuisse, Dominique [1 ,5 ]
Dutruc-Rosset, Gilles [1 ,5 ]
Tiraboschi, Gilles [3 ,5 ]
Dreyer, Matthias K. [6 ]
Maignan, Sebastien [4 ,5 ]
Chevalier, Alain [1 ,5 ]
Halley, Frank [1 ,5 ]
Bertrand, Philippe [2 ,5 ]
Burgevin, Marie-Claude [2 ,5 ]
Quarteronet, Dominique [2 ,5 ]
Rooney, Thomas [2 ,5 ]
机构：
[1] Med Chem, F-94300 Vitry Sur Seine, France
[2] CNS Dept, F-94300 Vitry Sur Seine, France
[3] CAS Mol Modelling, F-94300 Vitry Sur Seine, France
[4] CAS Struct Biol, F-94300 Vitry Sur Seine, France
[5] Sanofi Aventis, F-94300 Vitry Sur Seine, France
[6] Sanofi Aventis, D-65926 Frankfurt, Germany
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 06期
关键词：
Glycogen synthase kinase; GSK3; beta; Aminoindazole; Cdk's; SYNTHASE KINASE-3 GSK-3; CRYSTAL-STRUCTURE; PROTEIN;
D O I：
10.1016/j.bmcl.2010.01.114
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
From an HTS hit, a series of potent and selective inhibitors of GSK3 beta have been designed based on a Cdk2-homology model and with the help of several crystal structures of the compounds within Cdk2. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1985 / 1989
页数：5
相关论文
共 50 条
  • [1] Discovery and evaluation of dual CDK1 and CDK2 inhibitors
    Payton, M
    Chung, G
    Yakowec, P
    Wong, A
    Powers, D
    Xiong, L
    Zhang, N
    Leal, J
    Bush, TL
    Santora, V
    Askew, B
    Tasker, A
    Radinsky, R
    Kendall, R
    Coats, S
    CANCER RESEARCH, 2006, 66 (08) : 4299 - 4308
  • [2] Cdk1: the dominant sibling of Cdk2
    Tarig Bashir
    Michele Pagano
    Nature Cell Biology, 2005, 7 : 779 - 781
  • [3] Cdk1: the dominant sibling of Cdk2
    Bashir, T
    Pagano, M
    NATURE CELL BIOLOGY, 2005, 7 (08) : 779 - 781
  • [4] FOXM1c is activated by cyclin E/Cdk2, cyclin A/Cdk2, and cyclin A/Cdk1, but repressed by GSK-3α
    Wierstra, Inken
    Alves, Juergen
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 348 (01) : 99 - 108
  • [5] Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors
    Lee, Jinho
    Kim, Kyoung-Hee
    Jeong, Shinwu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (14) : 4203 - 4205
  • [6] Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach
    Tripathi, Sunil Kumar
    Singh, Sanjeev Kumar
    Singh, Poonam
    Chellaperumal, Palanisamy
    Reddy, Karnati Konda
    Selvaraj, Chandrabose
    JOURNAL OF MOLECULAR RECOGNITION, 2012, 25 (10) : 504 - 512
  • [7] Genetic substitution of Cdk1 by Cdk2 leads to embryonic lethality and loss of meiotic function of Cdk2
    Satyanarayana, Ande
    Berthet, Cyril
    Lopez-Molina, Javier
    Coppola, Vincenzo
    Tessarollo, Lino
    Kaldis, Philipp
    DEVELOPMENT, 2008, 135 (20): : 3389 - 3400
  • [8] Synthesis of potent oxindole CDK2 inhibitors
    Dermatakis, A
    Luk, KC
    DePinto, W
    BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (08) : 1873 - 1881
  • [9] Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation
    Welcker, M
    Singer, J
    Loeb, KR
    Grim, J
    Bloecher, A
    Gurien-West, M
    Clurman, BE
    Roberts, JM
    MOLECULAR CELL, 2003, 12 (02) : 381 - 392
  • [10] Clinical CDK2 Inhibitors: Trends to Selectivity and Efficacy
    Rusina, Polina V.
    Lisov, Alexey A.
    Denisova, Alexandra A.
    Gandalipov, Erik R.
    Novikov, Fedor N.
    Shtil, Alexander A.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2023, 18 (02) : 102 - 107
12345